首页> 美国卫生研究院文献>Stem Cells International >Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells
【2h】

Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

机译:间充质干细胞治疗缺血性疾病的研究进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs' survival and residential rate in vivo, timing of transplantation, particular microenvironment, and patient's clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases.
机译:缺血性疾病是一组疾病,包括缺血性脑血管疾病,缺血性心肌病(ICM)和糖尿病足以及其他疾病,它们正在成为全世界发病率和死亡率的主要原因。间充质干细胞(MSCs)已在动物模型和临床试验中用于治疗多种缺血性疾病。最近的许多出版物证明,MSCs治疗对于缺血性疾病患者是安全的,并且可以缓解症状。但是,许多因素可能会影响治疗效果,包括分娩途径,MSC的存活率和体内滞留率,移植时间,特定的微环境以及患者的临床状况。本文就缺血性脑血管疾病,ICM和糖尿病足的基于MSCs的治疗方法的现状,治疗潜力和详细因素进行了介绍和讨论。我们认为,MSCs移植将成为缺血性疾病患者的理想选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号